ASCO GU 2026: Updates in metastatic prostate cancer
![]()
ECC 2013 Immuno-Oncology Satellite Symposium supported by Bristol-Myers Squibb. Immuno-Oncology: the next new paradigm in cancer treatment?
Building upon the background of our current experience with the immuno-oncology compounds introduced in the prior presentations, Prof. Felip explores, from a clinical perspective, how these compounds differ from other modalities commonly used to treat patients with advanced cancer looking at the different response patterns and safety profiles.
To view the slides fullscreen click the square and arrows button at the bottom right of the player.
ASCO GU 2026: Updates in metastatic prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Highlights and analysis
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
EAU 2024: Bladder cancer latest
Multiple myeloma in a resource constrained setting